Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gains from Investment Securities (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Gains from Investment Securities data on record, last reported at $10.2 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 949.23% year-over-year to $10.2 million; the TTM value through Dec 2025 reached $10.2 million, up 1884.79%, while the annual FY2025 figure was $10.2 million, 1884.79% up from the prior year.
  • Gains from Investment Securities reached $10.2 million in Q3 2025 per TARS's latest filing, up from $125000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $10.2 million in Q3 2025 and bottomed at -$2.7 million in Q3 2021.
  • Average Gains from Investment Securities over 5 years is $829266.7, with a median of $125000.0 recorded in 2025.
  • Peak YoY movement for Gains from Investment Securities: tumbled 7385.19% in 2021, then surged 1686.67% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$2.0 million in 2021, then surged by 106.93% to $140000.0 in 2022, then surged by 857.14% to $1.3 million in 2023, then plummeted by 171.34% to -$956000.0 in 2024, then skyrocketed by 1167.89% to $10.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $10.2 million in Q3 2025, $125000.0 in Q2 2025, and -$125000.0 in Q1 2025.